Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients

Eric Lattmann, Pradnya Bhalerao, BL ShashiBhushan, Neeta Nargundkar, Pornthip Lattmann, K Sadasivan Pillai, PN Balaram
doi: https://doi.org/10.1101/2021.04.16.21255256
Eric Lattmann
1PNB Vesper Life Science Pvt. Ltd., Kochi, Kerala, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: balaram@pnbvesper.com eric.lattman@pnbvesper.com
Pradnya Bhalerao
2BJ Medical College and Sassoon General Hospital, Pune, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BL ShashiBhushan
3Victoria Hospital and Bangalore Medical College and Research Institute, Bangalore, Karnataka, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neeta Nargundkar
4Biosphere Clinical Research Pvt. Ltd. Thane, Maharashtra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pornthip Lattmann
1PNB Vesper Life Science Pvt. Ltd., Kochi, Kerala, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K Sadasivan Pillai
1PNB Vesper Life Science Pvt. Ltd., Kochi, Kerala, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PN Balaram
1PNB Vesper Life Science Pvt. Ltd., Kochi, Kerala, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: balaram@pnbvesper.com eric.lattman@pnbvesper.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTARCT

Objective To evaluate the efficacy and safety of PNB001 a CCK-A agonist and CCK-B antagonist, a new chemical entity with anti-inflammatory and immune stimulation properties, along with Standard of Care (SOC) in patients with moderate COVID-19 infection.

Design Multi-center, randomized, parallel group, comparative, open label study.

Setting Two tertiary-care hospitals in India.

Participants Patients with laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) within 2 days of randomization, having pneumonia with no signs of severe disease (severe disease means SpO2≤94% on room air), and any two of the following signs or symptoms suggestive of COVID-19: fever, cough, dyspnea, or hypoxia.

Interventions Patients were randomized 1:1 to receive PNB001 at an oral dose of 100 mg three times daily for 14 days with Standard of Care (PNB001+SOC) or only SOC.

Main outcome measures The primary endpoints were mean change in the 8-point WHO Ordinal Scale score from baseline by Day 14 and mortality rate by Day 28. The key secondary endpoints were percentage of patients showing change in clinical status using the ordinal scale, improvement in inflammatory segments in X-ray chest, reduction of days of hospitalization, duration of supplemental oxygen use, days to negative PCR for COVID-19 and change in inflammation markers Interlukin-6 (IL6) and C-reactive protein (CRP) from baseline by Day 14.

Results A total of 40 (20 in PNB 001+SOC arm and 20 in SOC arm) patients were randomized and received treatment. The primary endpoint showed significant clinical improvement from baseline to Day 14 with PNB001+SOC (0.22 Vs 1.12; P=0.0421). One patient in PNB001+SOC arm and two patients in SOC arm died (1 Vs 2; HR: 2.0 [95%CI=0.18, 22.05]; P=0.5637) by Day 28. At the end of the treatment by Day 14, more patients achieved zero ordinal scale in PNB001+SOC arm (17 Vs 12; P=0.0766). In the PNB001+SOC arm, change in mean chest X-ray score showed significant improvement (2.05 Vs 1.16; P=0.0321), and more patients quickly showed complete improvement (10 Vs 7; HR: 1.48 [95%CI=0.64, 3.44]; P=0.4309). In the PNB001+SOC arm, patients needed shorter duration of hospitalization in days (9.45 Vs 9.80) and more patients attained earlier discharge from the hospital (19 Vs 15; P=0.0486) with respect to days. The mean duration of supplemental oxygen requirement in days was shorter (5.45 Vs 7.10) and complete withdrawal from supplemental oxygen was more frequent with PNB001+SOC compared to SOC by Day 14 (17 Vs 13; P=0.1441). All patients in both the arms had negative PCR by the end of the study (18 Vs 17; P=0.6265) by similar time (7.6 Vs 7.0). Exploratory analysis done for IL-6, CRP, Neutrophil-Lymphocyte-Ratio (NLR), Platelet-Lymphocyte-Ratio (PLR) and Erythrocyte Sedimentation Rate (ESR) showed statistically significant reduction by Day 14 demonstrating PNB001’s anti-inflammatory and immunomodulatory properties. Lymphocyte and neutrophil counts also improved by Day 14. 11 adverse events (AE) in 8 patients were observed with PNB001+SOC compared to 13 AEs in 10 patients with SOC; none of the AEs in PNB001+SOC arm were related to PNB001. The most common AE were tachycardia and acute respiratory distress syndrome; there were isolated cases of hepatic enzyme elevation and hyperglycemia. Overall, safety profile was similar between PNB001+SOC and SOC arms.

Conclusions PNB001 with standard of care showed significant clinical improvement in moderate COVID-19 patients when compared to standard of care and was well tolerated by moderate COVID-19 patients.

Trial Registration CTRI/2020/10/028423

Competing Interest Statement

Eric Lattmann, Pornthip Lattmann, Sadasivan Pillai K, and Balaram PN are employees of PNB Vesper Life Science Pvt. Ltd.

Clinical Trial

CTRI/2020/10/028423

Funding Statement

The study was sponsored by PNB Vesper Life Science Pvt. Ltd.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study (Clinical Trial Registry of India: CTRI/2020/10/028423) was conducted by Biosphere Clinical Research Pvt. Ltd. Thane, Maharashtra following approval by the Drugs Controller General of India. The study protocol was approved by independent ethics committee of B.J. Government medical college and Sassoon General Hospital (ECR/280/Inst/Maha/2013/RR-19), and by independent ethics committee of Bangalore Medical College and Research Institute (ECR/302/Inst/KA/2013/RR-20). The study conduct was initiated after receiving the approval from both the independent ethics committee. The safety updates/reports including reports of suspected unexpected serious adverse reactions, were submitted to the independent ethics committee during the study. All the patients provided written informed consent prior to study enrolment.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 16, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients
Eric Lattmann, Pradnya Bhalerao, BL ShashiBhushan, Neeta Nargundkar, Pornthip Lattmann, K Sadasivan Pillai, PN Balaram
medRxiv 2021.04.16.21255256; doi: https://doi.org/10.1101/2021.04.16.21255256
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients
Eric Lattmann, Pradnya Bhalerao, BL ShashiBhushan, Neeta Nargundkar, Pornthip Lattmann, K Sadasivan Pillai, PN Balaram
medRxiv 2021.04.16.21255256; doi: https://doi.org/10.1101/2021.04.16.21255256

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (171)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8796)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1864)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (493)
  • Hematology (207)
  • HIV/AIDS (396)
  • Infectious Diseases (except HIV/AIDS) (10577)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1762)
  • Nursing (104)
  • Nutrition (267)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (966)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1846)
  • Public and Global Health (3992)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (536)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)